BPC-157 Dosage Guide: Subcutaneous, Oral, and Injection Protocols

At a Glance

How Much BPC-157 Should You Actually Take?

This is the question I get most often about BPC-157, and I want to be direct about the answer before we go deeper: nobody knows with certainty. There are no published human dose-finding studies for BPC-157. Every dosing protocol you encounter — including the ones used in clinical practice — is extrapolated from animal data using allometric scaling, combined with years of clinical observation.

That does not mean we are guessing blindly. It means we are working with the best available evidence, and I want you to understand exactly where that evidence comes from and where the gaps are.

In my clinical experience at Klinik St. Georg, the most commonly effective range for subcutaneous BPC-157 is 250-500 mcg administered once or twice daily. For oral administration targeting gastrointestinal conditions, 500-1000 mcg once daily on an empty stomach is the typical protocol. These are not magic numbers — they represent the range where clinical response appears most consistent with the fewest reported side effects.

How Animal Doses Translate to Human Doses

The foundational BPC-157 research from Professor Sikiric’s laboratory at the University of Zagreb used doses in the range of 10 mcg/kg body weight in rats, administered intraperitoneally or subcutaneously. Some studies used doses as low as 1 mcg/kg and as high as 50 mcg/kg.

Allometric scaling — the process of converting an effective animal dose to a human-equivalent dose — is not as simple as multiplying by body weight. The FDA guidance document on estimating initial safe starting doses recommends using body surface area conversion factors. For rat-to-human conversion, the standard factor is approximately 6.2, meaning you divide the rat dose (in mg/kg) by 6.2 to estimate the human equivalent dose in mg/kg.

Using this approach with the most commonly effective rat dose of 10 mcg/kg:

This gives you a human equivalent dose of roughly 100-150 mcg for a single administration. In practice, most clinicians use 250-500 mcg — approximately 2-4 times the strict allometric conversion. The rationale for this upward adjustment includes the difference between intraperitoneal administration in rats (which delivers the peptide directly to the peritoneal cavity with high local bioavailability) and subcutaneous injection in humans (which requires the peptide to be absorbed and distributed systemically before reaching the target tissue).

This is an honest assessment of the dosing rationale. It is educated estimation, not precise pharmacokinetics.

Subcutaneous Injection Protocol

Subcutaneous injection is the most common route of administration for musculoskeletal applications. The peptide is injected into the fatty tissue beneath the skin, ideally as close to the injury site as practical.

Standard Protocol

Injection Site Selection

For localized injuries — a torn rotator cuff, Achilles tendinopathy, lateral epicondylitis — injecting subcutaneously as close to the injury as anatomically reasonable is the standard approach. The hypothesis is that local injection creates a higher local concentration of the peptide at the target tissue. Whether this meaningfully increases efficacy compared to injection at a distant site has not been formally studied in humans.

For systemic applications or conditions that are not anatomically localized (such as general recovery or neuroprotection), injection into the abdominal subcutaneous fat is the most common approach. The abdomen offers consistent absorption and is technically simple for self-administration.

What I Tell My Patients

I typically start patients at 250 mcg once daily for the first week. If tolerated well and the clinical response is insufficient, I increase to 250 mcg twice daily or 500 mcg once daily. Starting at the lower end of the range allows me to assess tolerance before escalating. In my clinical experience, the difference between once and twice daily dosing is most apparent in acute injury recovery — where the additional dose seems to maintain tissue levels more consistently — and less important for chronic conditions.

Oral Dosing Protocol

BPC-157 is unusual among peptides in that it is stable in gastric juice. This acid stability is related to its high proline content and its biological origin as a fragment of a gastric protein. This stability makes oral administration a viable route, particularly for gastrointestinal targets.

Standard Oral Protocol

Why Higher Oral Doses?

The oral dose is typically higher than the subcutaneous dose because oral bioavailability is inherently lower. Even though BPC-157 survives the acidic gastric environment, it still must cross the intestinal epithelium to enter systemic circulation. First-pass metabolism in the liver further reduces the amount of peptide that reaches non-GI target tissues.

For gastrointestinal targets specifically — inflammatory bowel disease, NSAID-induced gastropathy, leaky gut — oral administration may actually be preferable because the peptide makes direct contact with the GI mucosa before systemic absorption. This is the one scenario where oral delivery may have an advantage over injection.

Oral vs. Subcutaneous: When to Use Which

Loading and Maintenance Protocols

Some practitioners use a loading-phase approach, starting with a higher dose or frequency for the first 1-2 weeks before transitioning to a maintenance dose. The rationale is to establish tissue levels more quickly during the acute phase of healing.

Example Loading Protocol

I want to be transparent: the loading protocol is not based on pharmacokinetic data. It is based on the clinical logic that tissue repair processes are most active in the first 1-2 weeks following injury, and higher peptide availability during this window may be beneficial. Some clinicians report better outcomes with loading phases. Others use a flat-dose protocol throughout and report equivalent results. Without comparative studies, this remains a matter of clinical judgment.

Body Weight Considerations

BPC-157 dosing is generally not adjusted for body weight in clinical practice, despite the fact that the allometric scaling from animal data is weight-based. The reason is pragmatic: the available evidence does not suggest a meaningful difference in response across the 200-500 mcg range for adults of varying body weights, and the therapeutic window appears wide enough that weight-based adjustments add complexity without clear benefit.

That said, for patients at the extremes of body weight:

These are conservative starting points. The nuance matters here — there is no evidence that a 100 kg patient needs exactly twice the dose of a 50 kg patient.

Cycling: Why and How

Most practitioners recommend cycling BPC-157 rather than continuous use. The typical pattern is 4-6 weeks on followed by 2-4 weeks off. The rationale for cycling includes:

1. Receptor sensitivity. Chronic exposure to any signaling peptide can theoretically lead to receptor downregulation. Cycling may preserve receptor sensitivity, though this has not been demonstrated specifically for BPC-157.

2. Healing timelines. Most acute musculoskeletal injuries show the majority of their tissue-level healing response within 4-6 weeks. Extended use beyond this window may offer diminishing returns.

3. Safety conservatism. Given the absence of long-term human safety data, limiting continuous exposure is a reasonable precautionary measure.

For chronic conditions such as inflammatory bowel disease, longer cycles of 6-8 weeks may be appropriate, with clinical reassessment between cycles to determine whether continued treatment is warranted.

Combination Protocols

BPC-157 is frequently combined with other peptides, most commonly TB-500 (Thymosin Beta-4 fragment). The rationale is that BPC-157 and TB-500 operate through partially distinct mechanisms — BPC-157 primarily through angiogenesis and growth factor modulation, TB-500 primarily through actin regulation and cell migration — and may have complementary effects on tissue repair.

A common combination protocol:

For a detailed comparison of these two peptides, see BPC-157 vs TB-500: Which Healing Peptide and When.

Reconstitution and Storage

BPC-157 is typically supplied as a lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water before injection.

Reconstitution Steps

1. Add bacteriostatic water slowly to the vial — do not shake, swirl gently
2. Common reconstitution: 2 mL bacteriostatic water to a 5 mg vial = 2,500 mcg/mL
3. This means 0.1 mL (10 units on an insulin syringe) = 250 mcg
4. Store reconstituted peptide refrigerated (2-8°C)
5. Use within 4 weeks of reconstitution

Concentration Table

What the Evidence Does Not Tell Us

Here is what the evidence shows: BPC-157 has consistent, reproducible effects across hundreds of animal studies at the doses described above. Here is what the evidence does not tell us:

• The optimal human dose for any specific indication
• Whether twice daily dosing is meaningfully better than once daily
• Whether local injection is superior to distal injection for localized injuries
• The ideal cycle length or rest period
• Whether body weight meaningfully affects the required dose
• Long-term safety at any dose

This is not unusual for a peptide at this stage of clinical development. But it is important that you understand the difference between a well-characterized pharmacological profile and a protocol built on extrapolation and clinical observation. The protocols in this article represent the latter.

The Bottom Line

BPC-157 dosing at 250-500 mcg subcutaneously once or twice daily for 4-6 week cycles is the most commonly used protocol, supported by allometric scaling from animal data and consistent clinical observation. Oral dosing at 500-1000 mcg is reasonable for gastrointestinal targets. All dosing remains extrapolated — not validated by human dose-finding trials. Work with a qualified physician, start conservatively, and adjust based on response.

For the full overview of BPC-157 mechanisms and evidence, see BPC-157: What the Research Actually Shows.

References

1. Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.” Inflammopharmacology. 2006;14(5-6):214-221. PMID: 17091493.
2. Nair AB, Jacob S. “A simple practice guide for dose conversion between animals and human.” J Basic Clin Pharm. 2016;7(2):27-31. PMID: 27057123.
3. Seiwerth S, et al. “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.” Curr Pharm Des. 2018;24(18):1972-1989. PMID: 29737246.
4. Hsieh MJ, et al. “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation of the expression of VEGF and NOS.” J Mol Med. 2017;95(3):323-333. PMID: 27866234.
5. Krivic A, et al. “Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and target for therapy.” J Orthop Res. 2006;24(5):982-989. PMID: 16609976.

Disclaimer: This article is for educational purposes and reflects current published research and clinical observation. It is not medical advice. BPC-157 is not FDA-approved for any therapeutic indication. Consult a qualified physician before pursuing any peptide therapy.